MX2011008197A - Compuestos de fenilimidazol. - Google Patents
Compuestos de fenilimidazol.Info
- Publication number
- MX2011008197A MX2011008197A MX2011008197A MX2011008197A MX2011008197A MX 2011008197 A MX2011008197 A MX 2011008197A MX 2011008197 A MX2011008197 A MX 2011008197A MX 2011008197 A MX2011008197 A MX 2011008197A MX 2011008197 A MX2011008197 A MX 2011008197A
- Authority
- MX
- Mexico
- Prior art keywords
- hydrogen atom
- lower alkyl
- group
- alkyl group
- lower alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se provee un producto farmacéutico (agente quimioterapéutico) efectivo en la prevención y tratamiento de hiperlipidemia, obesidad, etc.; un compuesto de fenilimidazol representado por la siguiente fórmula general (1):(ver fórmula (I)) en donde, R1 representa un átomo de hidrógeno, un grupo fenil-alquilo inferior que tiene opcionalmente un sustituyente, o un grupo piridil-alquilo inferior que iene opcionalmente un sustituyente, y el anillo de benceno y el anillo de piridina son opcionalmente sustituidos con 1 ó 2 sustituyentes seleccionados del grupo que consiste de átomos de halógeno, grupo ciano y grupos alquilo inferior halógeno-sustituidos; uno de R2 y R3 representa un átomo de hidrógeno y el otro representa un grupo alquilo inferior; R4 representa un grupo fenilo que tiene opcionalmente un sustituyente; R5 y R6 son los mismos o diferentes, y representan un átomo de hidrógeno o un grupo alquilo inferior; R7 y R8 son los mismos o diferentes, y representan un átomo de hidrógeno o un grupo alquilo inferior; sin embargo, cuando R1 representa un grupo fenil alquilo inferior no sustituido, R2 representa un grupo alquilo inferior, R3 representa un átomo de hidrógeno, R4 representa un grupo fenilo que tiene opcionalmente un sustituyente, y R5 representa un átomo de hidrógeno, R6 no es un átomo de hidrógeno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009023793 | 2009-02-04 | ||
| JP2009255980 | 2009-11-09 | ||
| PCT/JP2010/051469 WO2010090200A1 (ja) | 2009-02-04 | 2010-02-03 | フェニルイミダゾール化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011008197A true MX2011008197A (es) | 2011-08-17 |
Family
ID=42542093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011008197A MX2011008197A (es) | 2009-02-04 | 2010-02-03 | Compuestos de fenilimidazol. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8329739B2 (es) |
| EP (1) | EP2394996B8 (es) |
| JP (1) | JP5540227B2 (es) |
| KR (1) | KR101676889B1 (es) |
| CN (1) | CN102307861B (es) |
| AR (1) | AR075245A1 (es) |
| AU (1) | AU2010211753B2 (es) |
| BR (1) | BRPI1007902B1 (es) |
| CA (1) | CA2750704C (es) |
| DK (1) | DK2394996T3 (es) |
| ES (1) | ES2587942T3 (es) |
| HK (1) | HK1160123A1 (es) |
| HU (1) | HUE028840T2 (es) |
| MX (1) | MX2011008197A (es) |
| MY (1) | MY156539A (es) |
| PL (1) | PL2394996T3 (es) |
| PT (1) | PT2394996T (es) |
| RU (1) | RU2497811C2 (es) |
| SG (1) | SG172895A1 (es) |
| TW (1) | TWI435871B (es) |
| WO (1) | WO2010090200A1 (es) |
| ZA (1) | ZA201104932B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2280706T3 (da) * | 2008-05-14 | 2013-02-04 | Otsuka Pharma Co Ltd | Lipasa-aktiverende lipoproteinsammensætninger omfattende benzenderivater |
| KR20180032686A (ko) * | 2010-03-24 | 2018-03-30 | 아미텍 테러퓨틱 솔루션즈 인크 | 인산화효소 억제에 유용한 헤테로환 화합물 |
| ES2899757T3 (es) | 2014-12-19 | 2022-03-14 | Galderma Res & Dev | Compuestos heterocíclicos, su procedimiento de síntesis y su uso en medicina así como en cosmética |
| AU2016378154B2 (en) | 2015-12-25 | 2020-08-13 | Otsuka Pharmaceutical Factory, Inc. | Phenylimidazole compound |
| CN106946862B (zh) * | 2017-03-31 | 2019-09-03 | 枣庄学院 | 1-烷烃-6-甲基-5-硝基-1h-苯并[d]咪唑类化合物及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI57407C (fi) * | 1971-05-11 | 1980-08-11 | Ciba Geigy Ag | Analogifoerfarande foer framstaellning av nya farmakologiskt verksamma i 2-staellningen substituerade 4(5)-pyridyl-5(4)-fenyl-imidazoler |
| DE3411997A1 (de) * | 1984-03-31 | 1985-10-17 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue redox-indikatoren |
| JP2001226358A (ja) | 1999-10-12 | 2001-08-21 | Japan Tobacco Inc | Ｌｐｌ活性増強剤 |
| WO2008153957A1 (en) * | 2007-06-07 | 2008-12-18 | The Trustees Of Columbia University In The City Of New York | Uses of rage antagonists for treating obesity and related diseases |
| DK2280706T3 (da) * | 2008-05-14 | 2013-02-04 | Otsuka Pharma Co Ltd | Lipasa-aktiverende lipoproteinsammensætninger omfattende benzenderivater |
-
2010
- 2010-02-03 TW TW099103198A patent/TWI435871B/zh active
- 2010-02-03 MX MX2011008197A patent/MX2011008197A/es active IP Right Grant
- 2010-02-03 PT PT107385312T patent/PT2394996T/pt unknown
- 2010-02-03 US US13/145,041 patent/US8329739B2/en active Active
- 2010-02-03 DK DK10738531.2T patent/DK2394996T3/en active
- 2010-02-03 ES ES10738531.2T patent/ES2587942T3/es active Active
- 2010-02-03 JP JP2010549482A patent/JP5540227B2/ja active Active
- 2010-02-03 HU HUE10738531A patent/HUE028840T2/en unknown
- 2010-02-03 SG SG2011049533A patent/SG172895A1/en unknown
- 2010-02-03 WO PCT/JP2010/051469 patent/WO2010090200A1/ja active Application Filing
- 2010-02-03 RU RU2011136719/04A patent/RU2497811C2/ru active
- 2010-02-03 AU AU2010211753A patent/AU2010211753B2/en active Active
- 2010-02-03 PL PL10738531.2T patent/PL2394996T3/pl unknown
- 2010-02-03 BR BRPI1007902-5A patent/BRPI1007902B1/pt active IP Right Grant
- 2010-02-03 MY MYPI2011003582A patent/MY156539A/en unknown
- 2010-02-03 EP EP10738531.2A patent/EP2394996B8/en active Active
- 2010-02-03 KR KR1020117018550A patent/KR101676889B1/ko active IP Right Grant
- 2010-02-03 CN CN201080006527.5A patent/CN102307861B/zh active Active
- 2010-02-03 CA CA2750704A patent/CA2750704C/en active Active
- 2010-02-04 AR ARP100100313A patent/AR075245A1/es not_active Application Discontinuation
-
2011
- 2011-05-05 ZA ZA2011/04932A patent/ZA201104932B/en unknown
-
2012
- 2012-01-18 HK HK12100568.8A patent/HK1160123A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010211753A1 (en) | 2011-07-28 |
| AU2010211753B2 (en) | 2015-11-05 |
| TWI435871B (zh) | 2014-05-01 |
| JP5540227B2 (ja) | 2014-07-02 |
| JPWO2010090200A1 (ja) | 2012-08-09 |
| ZA201104932B (en) | 2012-09-26 |
| CN102307861B (zh) | 2014-10-29 |
| US20110275823A1 (en) | 2011-11-10 |
| US8329739B2 (en) | 2012-12-11 |
| EP2394996B1 (en) | 2016-06-22 |
| PL2394996T3 (pl) | 2016-12-30 |
| TW201033179A (en) | 2010-09-16 |
| CN102307861A (zh) | 2012-01-04 |
| ES2587942T3 (es) | 2016-10-27 |
| BRPI1007902B1 (pt) | 2022-01-04 |
| KR101676889B1 (ko) | 2016-11-16 |
| KR20110111300A (ko) | 2011-10-10 |
| WO2010090200A1 (ja) | 2010-08-12 |
| HUE028840T2 (en) | 2017-01-30 |
| SG172895A1 (en) | 2011-08-29 |
| CA2750704A1 (en) | 2010-08-12 |
| CA2750704C (en) | 2016-11-22 |
| PT2394996T (pt) | 2016-08-31 |
| BRPI1007902A2 (pt) | 2020-08-18 |
| HK1160123A1 (zh) | 2012-08-10 |
| RU2011136719A (ru) | 2013-03-10 |
| EP2394996A1 (en) | 2011-12-14 |
| AR075245A1 (es) | 2011-03-16 |
| RU2497811C2 (ru) | 2013-11-10 |
| DK2394996T3 (en) | 2016-08-01 |
| EP2394996A4 (en) | 2012-09-12 |
| MY156539A (en) | 2016-02-26 |
| EP2394996B8 (en) | 2016-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA104017C2 (en) | Pyridazinone compound and use thereof | |
| MY196864A (en) | Piperazine-substituted benzothiophene derivatives as antipsychotic agents | |
| PH12015500209A1 (en) | Partially saturated nitrogen-containing heterocyclic compound | |
| UA105185C2 (uk) | Піроли | |
| MX2010002243A (es) | Derivados fungicidas de 2-alquiltio-2-quinoliniloxi-acetamida. | |
| MX2009012345A (es) | Derivados de 3,3-espiroindolinona. | |
| TN2010000148A1 (en) | Amide compound | |
| MX2009010846A (es) | Proceso para producir compuesto pesticidas de benzamidas. | |
| MX351513B (es) | Compuesto de alquinilbenceno 3,5-disustituido y sales del mismo. | |
| GEP20105033B (en) | Therapeutic agent for diabetes | |
| UA115026C2 (uk) | Похідні гетероарилпіперидину та -піперазину як фунгіциди | |
| MX2010006143A (es) | Azolilmetiloxiranos, su uso y agentes que lo contienen. | |
| MX343625B (es) | Composiciones plagicidas. | |
| GEP20146079B (en) | Microbiocidal heterocycles | |
| MX2011006373A (es) | Compuestos de carbodiimida ciclica. | |
| MX2009010814A (es) | Compuestos de hidrazida y agente controlador de artropodos dañinos que contiene el mismo. | |
| MX2011008197A (es) | Compuestos de fenilimidazol. | |
| TW200722433A (en) | Phosphorus compounds, use thereof and flame retarding polyester fibers | |
| TW200609224A (en) | Organic compounds | |
| MX2014001023A (es) | Derivados de quinazolina. | |
| MX339557B (es) | Composicion plaguicida y su uso. | |
| GB201305247D0 (en) | Amide Compounds | |
| MY145368A (en) | Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof | |
| SG170778A1 (en) | Antitumoral compounds | |
| MY169359A (en) | Epoxy resin composition and electronic component device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |